Genetic markers and mutations may predict prognoses for certain CNS tumors


  • Expression of EZH2 may contribute to malignant progression of epithelioid glioblastoma (EGBM), and EZH2 overexpression or BRAF V600E mutations may be associated with shorter overall survival rates (OS) in EGBM and anaplastic pleomorphic xanthoastrocytoma (APXA).

Why this matters ?

  • Testing for EZH2 expression and BRAF V600E mutations may provide further information about the prognoses of patients with EGBM and APXA.